Key result
Warfarin exposure in Medicaid patients with nonvalvular atrial fibrillation was associated with a 27% reduction in thromboembolic events (p<0.01) without a significant increase in major bleeding.
Why the study?
Does warfarin exposure reduce thromboembolic events without increasing major bleeding in Medicaid patients with nonvalvular atrial fibrillation?
Population
4,355 Medicaid enrollees aged ≥50 years with nonvalvular atrial fibrillation in California, mean age 74…
Comparison
Warfarin exposure vs Periods of warfarin nonexposure
Design
Cohort
Authors
Loading...
Warfarin may confer net benefit in Medicaid AF; leaves open need for randomized confirmation before practice change.
Cohort (n=4,355)
Does warfarin exposure reduce thromboembolic events without increasing major bleeding in Medicaid patients with nonvalvular atrial fibrillation?
Effect estimate: 27% reduction
p-value: p=<0.01
In a Medicaid population with nonvalvular atrial fibrillation, warfarin use was associated with a 27% reduction in thromboembolic events without a significant increase in major bleeding risk.
Boulanger et al. (2006) conducted a cohort in Nonvalvular atrial fibrillation (NVAF) (n=4,355). Warfarin vs. Periods of nonexposure was evaluated on Hospitalization for thromboembolic events (27% reduction, p=<0.01). Warfarin exposure in Medicaid patients with nonvalvular atrial fibrillation was associated with a 27% reduction in thromboembolic events (p<0.01) without a significant increase in major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: